Previous models of anti-PD-(L)1 focused on using clinical data to identify potential biomarkers for pembrolizumab and ipilimumab in melanoma (Kumar et al., 2021) and for atezolizumab in breast cancer (Wang et al., 2021). Here, CD274 is linked to melanoma.